Mealey's Litigation Procedure - Class Certification Denied To End Payers, Indirect Purchasers In Pay-For-Delay Case

Mealey's Litigation Procedure - Class Certification Denied To End Payers, Indirect Purchasers In Pay-For-Delay Case

CHATTANOOGA, Tenn. - The federal judge in Tennessee overseeing multidistrict litigation involving claims that brand-name pharmaceutical company King Pharmaceuticals LLC and generic drug manufacturer Mutual Pharmaceutical Co. conspired to delay the entry of generic versions of Skelaxin into the market denied certification of an indirect purchaser class and an end-payer class on Jan. 30 (In re: Skelaxin $(Metaxalone$) Antitrust Litigation, No. 1:12-md-2343, E.D. Tenn.; 2014 U.S. Dist. LEXIS 11467).

Find full version on lexis Advance®
Access this news story on lexis.com®